Revolution Medicines Quarterly Income Statement
NASDAQ: RVMDHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
189.76+1.64 (+0.87%)
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Revolution Medicines revenue and earnings
Revolution Medicines reported a net loss of $644.4 million, compared with a loss of $247.8 million a year earlier. Diluted earnings per share came in at -$3.06.
Summary generated from market data by MetaCap's automated system. Methodology
Revolution Medicines income statement (quarterly)
| Quarter (USD) | Q2 20262026-06-30 | Q1 20262026-03-31 | Q4 20252025-12-31 | Q3 20252025-09-30 | Q2 20252025-06-30 | Q1 20252025-03-31 | Q4 20242024-12-31 | Q3 20242024-09-30 | Q2 20242024-06-30 | Q1 20242024-03-31 | Q4 20232023-12-31 | Q3 20232023-09-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | 0 | 0 | 0 | 0 | 742.00K | 0 |
| Revenue growth (YoY) | — | — | — | — | — | — | -100.00% | — | -100.00% | -100.00% | -95.16% | -100.00% |
| Operating Expenses | 505.13M | 445.22M | 361.63M | 315.27M | 264.71M | 240.76M | 216.31M | 175.71M | 156.64M | 140.86M | 180.72M | 123.25M |
| Research & Development | 394.92M | 343.97M | 294.94M | 262.51M | 224.13M | 205.75M | 188.10M | 151.75M | 134.93M | 118.02M | 148.48M | 107.73M |
| Operating Income | -505.13M | -445.22M | -361.63M | -315.27M | -264.71M | -240.76M | -216.31M | -175.71M | -156.64M | -140.86M | -179.98M | -123.25M |
| Interest Expense | 23.78M | 12.20M | 11.94M | 11.43M | 867.00K | 0 | 0 | 0 | — | — | — | — |
| Other Income (Expense) | -139.24M | -8.59M | -3.27M | 10.06M | 16.93M | 27.34M | 20.99M | 19.42M | 23.41M | 24.86M | 18.79M | 10.95M |
| Pretax Income | -644.37M | -453.82M | -364.89M | -305.21M | -247.79M | -213.42M | -195.32M | -156.29M | -133.23M | -116.00M | -161.19M | -112.30M |
| Income Tax | — | — | — | — | — | — | -753.00K | 0 | 0 | 0 | 343.00K | -3.87M |
| Net Income | -644.37M | -453.82M | -364.89M | -305.21M | -247.79M | -213.42M | -194.57M | -156.29M | -133.23M | -116.00M | -161.54M | -108.43M |
| Net Income growth (YoY) | — | — | — | — | — | — | — | — | — | — | — | — |
| EPS (Basic) | -3.06 | -2.29 | -1.90 | -1.61 | -1.31 | -1.13 | -1.13 | -0.94 | -0.81 | -0.70 | -1.23 | -0.99 |
| EPS (Diluted) | -3.06 | -2.29 | -1.90 | -1.61 | -1.31 | -1.13 | -1.13 | -0.94 | -0.81 | -0.70 | -1.23 | -0.99 |
| Shares Outstanding (Basic) | 210.89M | 198.10M | — | 189.23M | 188.58M | 188.15M | — | 166.84M | 165.14M | 164.73M | — | 109.23M |
| Shares Outstanding (Diluted) | 210.89M | 198.10M | — | 189.23M | 188.58M | 188.15M | — | 166.84M | 165.14M | 164.73M | — | 109.23M |
| EBITDA | -502.68M | -442.88M | -359.36M | -313.74M | -262.42M | -239.07M | -214.57M | -174.07M | -155.00M | -139.32M | -178.68M | -121.95M |
| Operating Margin | — | — | — | — | — | — | — | — | — | — | -24256.47% | — |
| Net Margin | — | — | — | — | — | — | — | — | — | — | -21770.49% | — |
This table shows 12 quarterly periods of Revolution Medicines's income statement, from Q2 2026 back to Q3 2023, across 16 line items including revenue, operating expenses, research & development. Values in USD; B = billions, M = millions. Fiscal periods follow RVMD's reporting calendar. What is a income statement?